Axsome Therapeutics (AXSM) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Axsome Therapeutics Revenue Highlights


Latest Revenue (Y)

$270.60M

Latest Revenue (Q)

$87.17M

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Axsome Therapeutics Revenue by Period


Axsome Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$270.60M440.80%
2022-12-31$50.04M100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31--

Axsome Therapeutics generated $270.60M in revenue during NA 2023, up 440.80% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Axsome Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30$87.17M16.22%
2024-03-31$75.00M4.85%
2023-12-31$71.53M23.77%
2023-09-30$57.79M23.76%
2023-06-30$46.70M-50.62%
2023-03-31$94.58M288.06%
2022-12-31$24.37M44.67%
2022-09-30$16.85M91.00%
2022-06-30$8.82M100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30--

Axsome Therapeutics generated $87.17M in revenue during Q2 2024, up 16.22% compared to the previous quarter, and up 92.17% compared to the same period a year ago.

Axsome Therapeutics Revenue Breakdown


Axsome Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23
Product$202.46M
License$65.73M
Royalty$2.40M

Axsome Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (74.82%), License (24.29%), and Royalty (0.89%).

Quarterly Revenue by Product

Product/ServiceMar 24Dec 23Sep 23Jun 23Mar 23
Royalty$903.00K$783.00K$667.00K$683.00K$272.00K
Product$74.10M$70.75M$57.13M$46.02M$28.57M
License--$65.73M$65.73M-

Axsome Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (98.80%), and Royalty (1.20%).

Axsome Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22
UNITED STATES$197.22M-
Non-US$65.73M$900.00K

Axsome Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (75.00%), and Non-US (25.00%).

Quarterly Revenue by Country

CountryMar 24Dec 23Sep 23Jun 23Mar 23
Non-US$903.00K-$65.73M$600.00K$1.70M
UNITED STATES$73.27M$141.44M$55.78M--

Axsome Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (98.78%), and Non-US (1.22%).

Axsome Therapeutics Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
INCYIncyte$3.70B$962.99M
SRPTSarepta Therapeutics$1.24B$413.46M
ACADACADIA Pharmaceuticals$726.44M$241.96M
AMLXAmylyx Pharmaceuticals$380.79M$88.64M
AXSMAxsome Therapeutics$270.60M$87.17M
BPMCBlueprint Medicines$249.38M$128.18M
TGTXTG Therapeutics$233.66M$73.47M
MCRBSeres Therapeutics$126.33M-
VKTXViking Therapeutics--
PDSBPDS Bio--
DAWNDay One Biopharmaceuticals-$20.07M
MDGLMadrigal Pharmaceuticals-$62.17M
TERNTerns Pharmaceuticals--
AKROAkero Therapeutics--
HEPAHepion Pharmaceuticals--

AXSM Revenue FAQ


Axsome Therapeutics's yearly revenue for 2023 was $270.6M, representing an increase of 440.80% compared to 2022. The company's yearly revenue for 2022 was $50.04M, representing an increase of 100.00% compared to 2021. AXSM's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.

Axsome Therapeutics's quarterly revenue for Q2 2024 was $87.17M, a 16.22% increase from the previous quarter (Q1 2024), and a 86.65% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $75M, a 4.85% increase from the previous quarter (Q4 2023), and a -20.70% decrease year-over-year (Q1 2023). AXSM's quarterly revenue for Q4 2023 was $71.53M, a 23.77% increase from the previous quarter (Q3 2023), and a 193.50% increase year-over-year (Q4 2022).

Axsome Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.

Axsome Therapeutics's revenue streams in c 23 are Product, License, and Royalty. Product generated $202.46M in revenue, accounting 74.82% of the company's total revenue License generated $65.74M in revenue, accounting 24.29% of the company's total revenue Royalty generated $2.4M in revenue, accounting 0.89% of the company's total revenue

For the fiscal year ending Dec 23, the largest source of revenue of Axsome Therapeutics was Product. This segment made a revenue of $202.46M, representing 74.82% of the company's total revenue.